Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 4,175 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control comparison Clear all

Conditions: Opioid Use Disorder, Opioid Withdrawal, Substance Use Disorders
Interventions: Ibogaine Hydrochloride, Extended-release naltrexone injection, 380 mg, Matching Oral Placebo, Matching Intramuscular Placebo, My-E-Health SENTINEL Digital Monitoring and Human-Gated Escalation Platform, Standardized Psychological Preparation, Integration and Recovery Support, Garmin-Enabled Longitudinal Wellness Monitoring; Drug · Device · Behavioral + 1 more
Lead sponsor: Clive Michelsen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Basalt, Colorado

Conditions: HIV Positive
Interventions: Not listed
Lead sponsor: QIAGEN Gaithersburg, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cirrhosis, Hepatic Encephalopathy, Minimal Hepatic Encephalopathy, Covert Hepatic Encephalopathy
Interventions: 25% IV albumin, Placebo; Biological · Other
Lead sponsor: Hunter Holmes Mcguire Veteran Affairs Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Wrinkle
Interventions: Tixel, Laser; Device
Lead sponsor: Novoxel Ltd.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Psoriatic Arthritis
Interventions: methotrexate (MTX), adalimumab (ADA); Drug · Biological
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 12
States / cities: Sun City, Arizona • Miami, Florida • Vernon Hills, Illinois + 9 more

Conditions: Dry Eye
Interventions: HL036 ophthalmic solution, Placebo vehicle solution; Biological · Other
Lead sponsor: HanAll BioPharma Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Lewiston, Maine • Andover, Massachusetts

Conditions: Burns
Interventions: RES (Regenerative Epidermal Suspension) prepared using the RECELL® Autologous Cell Harvesting Device, Mepilex® Ag Wound Dressing, Conventional autografting (only when indicated); Device · Combination Product · Procedure
Lead sponsor: Avita Medical; Industry
Eligibility: 1 Year to 16 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 9
States / cities: Phoenix, Arizona • Tampa, Florida • New Orleans, Louisiana + 6 more

Conditions: Musculoskeletal Diseases
Interventions: Physical Therapist, Primary Care Provider; Other
Lead sponsor: Temple University; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Fort Sam Houston, Texas

Conditions: Asthma
Interventions: GSK5784283, Placebo, Standard of care; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 11
States / cities: San Diego, California • Miami, Florida • Miami Lakes, Florida + 8 more

Conditions: Influenza
Interventions: Influenza Virus Quadrivalent Inactivated Vaccine, Sodium Chloride, 0.9%, VRC-FLUNPF099-00-VP (H1ssF_3928); Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pregnancy Related, Atopic Dermatitis
Interventions: Ruxolitinib Cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 15 Years to 50 Years · Female only
Enrollment: 958 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 1
States / cities: Morrisville, North Carolina

Conditions: Awareness During General Anesthesia
Interventions: Bispectral Index Monitor, Electronic MAC alert; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 100 Years
Enrollment: 22,185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Chronic Idiopathic Constipation
Interventions: Lubiprostone, Placebo; Drug
Lead sponsor: Sucampo Pharma Americas, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 552 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 67
States / cities: Birmingham, Alabama • Foley, Alabama • Little Rock, Arkansas + 58 more

Conditions: Sepsis, Trauma Injury
Interventions: Human feces collection; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 110 Years
Enrollment: 468 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Snake Bite, Blood Coagulation Disorders
Interventions: Anavip, CroFab; Biological
Lead sponsor: Instituto Bioclon S.A. de C.V.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: ADHD
Interventions: Placebo, 200mg SPN-812, 400mg SPN-812; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 10
States / cities: Long Beach, California • Lauderhill, Florida • Orlando, Florida + 7 more

Conditions: Energy Intake, Substrate Utilization, Hormones, Satiety
Interventions: Maltodextrin supplement, Whey supplement, Water; Dietary Supplement
Lead sponsor: Ohio University; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Athens, Ohio

Conditions: Maternal Dietary Diversity, Iron-Folic Acid Supplementation, Early Initiation of Breastfeeding
Interventions: Health Facility Interventions, Community Interventions, Health System Interventions; Behavioral
Lead sponsor: International Food Policy Research Institute; Other
Eligibility: 15 Years to 49 Years · Female only
Enrollment: 4,256 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Hysterotomy Closure
Interventions: Stratafix synthetic barbed suture; Procedure
Lead sponsor: Evangelical Community Hospital, Lewisburg, PA; Other
Eligibility: 16 Years to 50 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Lewisburg, Pennsylvania

Conditions: Diabetes Type 2
Interventions: Retatrutide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 537 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 29
States / cities: Scottsdale, Arizona • Tucson, Arizona • Canoga Park, California + 25 more

Conditions: Essential Thrombocythemia
Interventions: Bomedemstat, Anagrelide, Busulfan, Interferon alfa/pegylated interferon alfa 2a/pegylated interferon alfa 2b, Ruxolitinib; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 15
States / cities: Glendale, Arizona • Glendale, California • Stanford, California + 12 more

Conditions: PTSD
Interventions: Group Cognitive Behavioral Treatment (GCBT), Present Centered Group Treatment; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 2
States / cities: Boston, Massachusetts • Providence, Rhode Island

Conditions: Diabetic Macular Edema
Interventions: Luminate 1.0mg, Luminate 2.0mg, Luminate 3.0mg, Avastin, Luminate 0.5mg; Drug
Lead sponsor: Allegro Ophthalmics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 17
States / cities: Phoenix, Arizona • Beverly Hills, California • Mountain View, California + 14 more

Conditions: Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions: Fasinumab, Diclofenac, Celecoxib, Matching placebo; Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 71
States / cities: Anniston, Alabama • Mobile, Alabama • Chandler, Arizona + 63 more

Search by objective public record fields.

Medically Supervised Ibogaine With 12-Month Digital Recovery Support for Opioid Use Disorder

Evaluation of a Blood Test to Measure Immune Function in HIV Positive People Compared With HIV Negative People

HEAL STUDY (Hepatic Encephalopathy and Albumin Study)

A Safety and Effectiveness Study of the Tixel Device, (Fractional Peri-orbital Wrinkles Treatment ) Compared With Laser

A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

A Study to Assess Efficacy of HL036 in Subjects With Dry Eyes

RES® Prepared With RECELL® Compared to Standard of Care Dressings of Partial-thickness Burns in Ages 1-16 Years

Back-on-Track Studying Early Quality Care

A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-2)

A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults

Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population

Bispectral Index (BIS) Versus Electronic Alerts in the Prevention of Anesthesia Awareness: the Michigan Awareness Control Study

Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo

Microbiome Dysfunction in Surgical Intensive Care Unit Survivors

A Comparison of Crotalinae Equine Immune F(ab)2 Antivenom (Anavip) and Crotalidae Polyvalent Immune Fab,

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD

Breakfast Consumption and Energy Balance in Active Adult Males

A Feasibility Study of Integrating Maternal Nutrition Interventions Into Antenatal Care Services in Ethiopia

Study to Compare Suture Material in Closure of Uterine Incision in Cesarian Section

Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

Group Treatment for PTSD: A Randomized Clinical Trial With Veterans

Phase 2 Randomized Clinical Trial of Luminate® as Compared to Avastin® in the Treatment of Diabetic Macular Edema

Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip